How AI Is Changing Cancer Diagnosis in Korean Hospitals

In 2024, a study published in The Lancet Digital Health found that an AI system developed by the Korean company Lunit detected breast cancer on mammograms with greater sensitivity than the average radiologist. The AI did not miss cancers that human eyes overlooked. It flagged suspicious areas that even experienced radiologists had rated as normal. Used alongside radiologists, it improved cancer detection rates by 10-12% while simultaneously reducing false positives.

This is not a future possibility. It is happening now, in Korean hospitals, on real patients.

Korea has become a global leader in deploying AI-assisted medical diagnostics, not as a research curiosity confined to academic papers, but as a routine clinical tool embedded in the daily workflow of radiologists, pathologists, and oncologists at the country’s major hospitals. For international patients, this means that getting screened or diagnosed at a Korean hospital increasingly involves AI systems that serve as a second set of eyes, catching abnormalities that a single human reader might miss.

This article explains what medical AI diagnostics actually do, which Korean companies are leading the field, which hospitals use these systems, and what this means practically for patients seeking cancer screening or diagnosis in Korea.

What AI Medical Diagnostics Actually Do

Medical AI diagnostics are not replacing doctors. They are augmenting them. The technology works as a “second reader,” an additional analysis layer that runs alongside the physician’s own interpretation.

Here is the typical workflow:

1. A patient undergoes imaging (chest X-ray, mammogram, CT scan) or a tissue biopsy.
2. The images are processed through an AI algorithm that has been trained on hundreds of thousands (sometimes millions) of annotated medical images.
3. The AI generates a probability map highlighting areas of concern, with confidence scores for specific findings (nodule, mass, calcification, etc.).
4. The radiologist or pathologist reviews both the original images AND the AI’s analysis.
5. The physician makes the final diagnosis, using the AI output as one input among many.

The AI does not make treatment decisions. It does not interact with patients. It is a tool that helps the physician see more accurately and consistently.

Why AI Helps

Fatigue resistance: A radiologist reading 100 chest X-rays in a day inevitably loses some attention. Study after study shows that detection accuracy decreases over long reading sessions. AI does not fatigue. It applies the same analytical rigor to image #100 as to image #1.

Pattern detection beyond human vision: AI can identify subtle patterns in medical images that are below the threshold of human visual perception. Tiny changes in tissue density, barely visible micro-calcifications, early-stage nodules smaller than 5mm. These are where AI adds the most value.

Consistency: Different radiologists reading the same image may reach different conclusions. This inter-reader variability is well-documented in radiology. AI provides a consistent baseline analysis that reduces this variability.

Speed: AI analysis takes seconds. In emergency settings (trauma, stroke), this speed can accelerate treatment decisions.

Lunit: Korea’s AI Diagnostics Leader

Lunit (pronounced “L-unit,” short for “Learning Unit”) is a Seoul-based medical AI company founded in 2013 by researchers from the Seoul National University machine learning lab. It has become one of the most commercially successful and clinically validated medical AI companies in the world.

Lunit INSIGHT CXR (Chest X-Ray AI)

What it does: Analyzes chest X-rays for 10 major abnormalities including lung nodules, consolidation (pneumonia), pleural effusion, cardiomegaly, and atelectasis.

Performance: In published studies, Lunit INSIGHT CXR achieved:
– 97-99% sensitivity for lung nodules (meaning it correctly identified 97-99% of nodules present)
– 95-98% specificity (meaning a low false positive rate)
– Area Under the Curve (AUC) of 0.99 for major thoracic abnormalities, a near-perfect diagnostic performance metric

Clinical impact: When deployed at Seoul National University Bundang Hospital, the system reduced missed findings on chest X-rays by over 20%. Radiologists who used Lunit INSIGHT as a second reader detected more abnormalities than radiologists who read alone.

Regulatory status: CE-marked in Europe, FDA-cleared in the United States (510(k) clearance), and approved by Korea’s MFDS. It is one of the few medical AI products with regulatory clearance in all three major markets.

Lunit INSIGHT MMG (Mammography AI)

What it does: Analyzes mammograms for breast cancer, assigning a probability score to each exam and highlighting suspicious regions.

Performance:
– 90-96% sensitivity for breast cancer detection (varies by study and cancer type)
– Demonstrated to reduce radiologist recall rates (unnecessary follow-up exams) by 5-10%
– In the Lancet Digital Health study (2024), use of Lunit AI alongside radiologists improved cancer detection by 10-12% compared to radiologists reading alone

Clinical impact: In Korea, where breast cancer screening mammography is covered by national health insurance for women over 40, the addition of AI-assisted reading at hospitals like Samsung Medical Center has improved early detection rates. Early detection of breast cancer (stage 0-1) dramatically improves survival rates and reduces the need for aggressive treatment.

Lunit SCOPE (Pathology AI)

What it does: Analyzes digitized pathology slides (tissue biopsies) to identify cancer cells and biomarkers. Specific products include:

• Lunit SCOPE IO: Quantifies PD-L1 expression in tumor tissue. PD-L1 is a biomarker that determines whether a patient is eligible for immunotherapy drugs (pembrolizumab, nivolumab, etc.). Accurate PD-L1 scoring directly affects treatment decisions.
• Lunit SCOPE HER2: Assesses HER2 expression in breast cancer tissue, another critical biomarker that determines treatment eligibility (trastuzumab).

Why this matters for patients: Biomarker testing is not just an academic exercise. If your PD-L1 score is inaccurately assessed, you might be denied immunotherapy that could save your life, or given immunotherapy that will not work for your specific tumor. AI-assisted biomarker quantification reduces the subjectivity inherent in pathologist visual scoring.

Other Korean Medical AI Companies

Lunit is the most prominent but not the only Korean medical AI company:

Vuno

Seoul-based AI company with products for:
– Chest X-ray analysis (Vuno Med-Chest X-ray)
– ECG analysis (detecting atrial fibrillation and other cardiac arrhythmias)
– Bone age assessment (pediatrics)
– Fundoscopy (diabetic retinopathy screening)

Vuno’s products are deployed in multiple Korean hospitals and have received CE marking and Korean MFDS approval.

JLK

A Korean AI company focused on stroke and neurological imaging:
– JBS-01K: Analyzes brain CT scans for hemorrhagic stroke, providing automated detection and measurement of intracranial hemorrhage volume. This is critical in emergency settings where minutes matter.
– ATROSCAN: Analyzes brain MRI for neurodegenerative disease markers (brain atrophy patterns associated with Alzheimer’s disease).

Coreline Soft

Specializes in lung and cardiac imaging AI:
– AVIEW LCS: Lung cancer screening AI for low-dose CT scans. Detects and measures pulmonary nodules, tracks changes over time, and classifies nodules by risk level.
– AVIEW QCT: Quantitative cardiac CT analysis.

Which Korean Hospitals Use AI Diagnostics

AI diagnostic tools are deployed at Korea’s major hospitals. Here is a breakdown:

Samsung Medical Center

One of the earliest and most aggressive adopters of medical AI in clinical practice. Samsung MC uses:
– Lunit INSIGHT for chest X-rays and mammography
– AI-assisted pathology for biomarker assessment
– AI tools for colonoscopy (real-time polyp detection during endoscopy)

Samsung Medical Center’s Cancer Center treats the highest volume of cancer patients in Korea and uses AI diagnostics as a standard part of screening and diagnostic workups.

Asan Medical Center

Korea’s highest-volume hospital (2,700+ beds) uses AI tools across radiology, pathology, and emergency medicine. Asan has also been a key site for clinical validation studies of multiple Korean AI products.

Severance Hospital (Yonsei)

Severance Hospital integrates AI diagnostics into its radiology and pathology departments. As a research-intensive university hospital (Newsweek #40 globally), Severance both deploys commercial AI tools and conducts ongoing research to validate and improve them. Severance’s Department of Radiology has published numerous studies on AI-assisted detection of lung nodules, breast cancer, and liver lesions.

Seoul St. Mary’s Hospital

Seoul St. Mary’s Hospital uses AI tools in its cancer center, with particular application in the hospital’s world-renowned bone marrow transplant program (ranked #5 globally). AI-assisted pathology helps with precise characterization of hematologic malignancies.

Korea University Anam Hospital

Korea University Anam Hospital has adopted AI-assisted imaging as part of its health screening programs. For international patients coming for full checkups ($490-$5,330), this means that chest X-rays and other screening images benefit from AI analysis alongside radiologist review.

Broader Deployment

Beyond these major hospitals, Lunit INSIGHT alone is deployed in over 4,000 medical facilities across 60+ countries. In Korea, the density of AI diagnostic deployment is particularly high because the Korean government has actively supported medical AI adoption through regulatory frameworks and reimbursement policies.

Korea’s Regulatory Framework for Medical AI

Korea’s approach to regulating medical AI is one of the reasons the country leads in clinical deployment.

MFDS Approval Pathway

Korea’s Ministry of Food and Drug Safety (MFDS) classifies medical AI software as a medical device and has established a clear approval pathway. Key features:

• Tiered classification: AI tools are classified based on risk level (Class I-IV). Most diagnostic AI falls in Class II or III, requiring clinical evidence of safety and efficacy.
• Real-world evidence accepted: MFDS accepts real-world clinical data (not just randomized controlled trials) as evidence for AI medical device approval. This accelerates the approval process without compromising safety standards.
• Post-market surveillance: Approved AI tools are subject to ongoing monitoring for performance degradation or safety signals.
• Regular updates: MFDS has issued specific guidance documents for AI-based medical devices, addressing issues like algorithmic bias, data drift, and continuous learning systems. These guidelines are updated regularly as the technology evolves.

Reimbursement

In 2022, Korea became one of the first countries to establish a national health insurance reimbursement code for AI-assisted medical image analysis. This means that when a Korean hospital uses an approved AI tool to assist in reading your chest X-ray or mammogram, the cost is at least partially covered by the national insurance system, which in turn incentivizes hospitals to adopt the technology.

For international patients (who pay out-of-pocket or through private insurance), AI-assisted analysis is typically included in the standard fee for imaging studies. You do not pay extra for the AI analysis at most Korean hospitals.

Comparison to Other Countries

The US has approved more AI medical devices overall, but Korea’s reimbursement framework and hospital adoption rates mean that Korean patients are more likely to actually benefit from AI diagnostics in routine clinical practice.

What This Means for International Patients

If you are coming to Korea for cancer screening or diagnosis, here is how AI diagnostics practically affects your care:

During a Health Checkup

When you undergo a full health checkup at a Korean hospital, your imaging studies (chest X-ray, mammogram if applicable, low-dose CT if included in your package) are likely to be analyzed by both a radiologist and an AI system. This dual-read approach means:

• Lower chance of a missed finding on screening images
• More consistent detection of early-stage abnormalities
• Quantitative measurements (nodule size, density) that aid in risk stratification

See our guide to health checkups in Korea for screening package details.

During Cancer Diagnosis

If you are coming to Korea specifically for cancer diagnosis or second opinion, AI-assisted tools add value at multiple stages:

1. Imaging review: AI highlights areas of concern on CT, MRI, or X-ray, ensuring the radiologist does not overlook subtle findings.
2. Biopsy analysis: AI-assisted pathology provides more precise biomarker quantification (PD-L1, HER2, etc.), which directly determines treatment eligibility.
3. Treatment planning: AI-generated tumor measurements and characteristics feed into multi-disciplinary tumor board discussions where oncologists, surgeons, and radiation oncologists collectively determine the optimal treatment plan.

During Treatment Monitoring

For patients undergoing cancer treatment in Korea (chemotherapy, immunotherapy, radiation), AI tools assist in monitoring treatment response:
– Tracking tumor size changes on serial CT scans with greater precision than manual measurement
– Detecting new lesions or metastatic disease early
– Quantifying treatment-related side effects (lung toxicity on chest X-ray, cardiac changes on CT)

Limitations of Current Medical AI

Transparency requires acknowledging what AI cannot do:

AI does not diagnose. It provides probability assessments and highlights regions of interest. The physician makes the final diagnosis by integrating AI output with clinical history, physical examination, lab results, and other imaging.

AI is trained on specific populations. Most current AI models were trained predominantly on Korean and East Asian patient data. Performance on patients from other ethnic backgrounds may differ slightly, particularly for conditions with population-specific prevalence patterns. Major AI companies like Lunit are actively expanding their training datasets to be more globally representative.

AI can generate false positives. While AI reduces missed findings, it can also flag benign findings as suspicious, leading to unnecessary follow-up imaging or biopsies. The physician’s role is to contextualize AI findings and prevent over-investigation.

AI does not replace clinical judgment. A 5mm lung nodule flagged by AI in a 25-year-old non-smoker requires different management than the same finding in a 65-year-old heavy smoker. AI provides the detection; the physician provides the judgment.

The Future: What Is Coming

Korean medical AI is evolving rapidly. Developments expected in the next 2-5 years:

Multi-modal AI: Systems that integrate imaging, pathology, genomics, and clinical data to provide complete diagnostic assessments. Rather than analyzing a chest X-ray in isolation, the AI would consider the X-ray alongside blood biomarkers, patient history, and genetic risk factors.

Real-time surgical AI: AI systems that analyze imaging during surgery to guide surgeons in real-time. Early versions are already in use for neurosurgery (identifying tumor margins) and endoscopy (detecting polyps during colonoscopy).

Predictive AI: Moving beyond detection to prediction: identifying patients at high risk of developing cancer before it is visible on imaging, based on subtle imaging patterns and clinical data.

Liquid biopsy + AI: Combining blood-based cancer markers (circulating tumor DNA) with AI analysis for non-invasive cancer screening. Several Korean research institutions are active in this field.

Korea’s combination of advanced healthcare infrastructure, strong AI research talent (Seoul National University, KAIST, POSTECH), supportive regulatory environment, and large hospital networks for clinical validation positions it as one of the top 2-3 countries globally for medical AI development and deployment.

Getting Cancer Screening or Diagnosis in Korea

For international patients considering cancer screening or seeking a second opinion on a cancer diagnosis, Korea offers a combination of world-class medical expertise, advanced AI-assisted diagnostics, and costs that are a fraction of US pricing.

A thorough cancer screening at a Korean hospital (including low-dose CT, tumor markers, endoscopy, and AI-assisted image analysis) costs $1,000-$3,000, compared to $5,000-$15,000 for equivalent screening in the US.

We coordinate the entire process: hospital selection matched to your specific concern, appointment scheduling, translation, and follow-up coordination.

Learn more about disease treatment options in Korea.

Talk to Our Team →